How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies

In the last five years, everolimus has demonstrated efficacy in the treatment of neuroendocrine tumors (NETs) of different origins; its efficacy and safety were explored in the RADIANT trials, the last of which (RADIANT-4) has been recently published (December 2015). Overall, evidence collected from...

Descripción completa

Detalles Bibliográficos
Autores principales: Pusceddu, Sara, De Braud, Filippo, Russo, Giuseppe Lo, Concas, Laura, Femia, Daniela, Vernieri, Claudio, Indini, Alice, Formisano, Barbara, Buzzoni, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190138/
https://www.ncbi.nlm.nih.gov/pubmed/27057638
http://dx.doi.org/10.18632/oncotarget.8601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190138/
https://www.ncbi.nlm.nih.gov/pubmed/27057638
http://dx.doi.org/10.18632/oncotarget.8601

Ejemplares similares